general liability

Vast scope of industry expertise in mass tort litigation and resolution
The attorneys at Peters & Nye successfully represent insurers in connection with high profile, high-dollar value mass tort litigation arising out of environmental disasters, defective products and toxic torts. In addition to these high exposure cases, our attorneys provide coverage opinions and loss analysis in connection with individual claims submitted under general liability, umbrella, and excess policies. This vast breadth of experience allows our attorneys to efficiently evaluate the potential exposure and key coverage issues presented in such cases.

We have served as national monitoring counsel in numerous pharmaceutical product liability cases involving Phen-Fen, diabetes drugs, anti-depressants, non-steroidal anti-inflammatory drugs, statins, intestinal drugs, childhood vaccines, and many over-the-counter medications. Additionally, our attorneys have handled many other high profile product liability matters, including breast implants, automobile component defects, latex and protective gear. With respect to environmental claims, we have represented insurers in connection with asbestos litigation, lead paint and oil spills, including the largest pollution case in U.S. history resulting from the Deepwater Horizon explosion in the Gulf of Mexico.

Through this vast scope of coverage experience, our attorneys have developed and employed industry-specific tools that quickly and cost-effectively allow us to investigate and evaluate large volumes of data in order to provide clients with a reliable assessment of loss exposure and reserve analysis. Tools include claim and loss spreadsheets, audit forms, and searchable databases. Additionally, our attorneys are versed in analyzing regulatory reports, manufacturer product data, and internal and external clinical studies and adverse event reports.

Through our expert knowledge, experience, creativity and industry reputation, our attorneys are able to obtain favorable results at cost-effective pricing.